Department of Surgery and of Biomedicine, University Hospital Basel, Hebelstrasse 20, 4031 Basel, Switzerland.
Biomaterials. 2010 Dec;31(34):8946-52. doi: 10.1016/j.biomaterials.2010.08.009. Epub 2010 Aug 25.
Apart from partial or total joint replacement, no surgical procedure is currently available to treat large and deep cartilage defects associated with advanced diseases such as osteoarthritis. In this work, we developed a perfusion bioreactor system to engineer human cartilage grafts in a size with clinical relevance for unicompartmental resurfacing of human knee joints (50 mm diameter × 3 mm thick). Computational fluid dynamics models were developed to optimize the flow profile when designing the perfusion chamber. Using the developed system, human chondrocytes could be seeded throughout large 50 mm diameter scaffolds with a uniform distribution. Following two weeks culture, tissues grown in the bioreactor were viable and homogeneously cartilaginous, with biomechanical properties approaching those of native cartilage. In contrast, tissues generated by conventional manual production procedures were highly inhomogeneous and contained large necrotic regions. The unprecedented engineering of human cartilage tissues in this large-scale opens the practical perspective of grafting functional biological substitutes for the clinical treatment for extensive cartilage defects, possibly in combination with surgical or pharmacological therapies to support durability of the implant. Ongoing efforts are aimed at integrating the up-scaled bioreactor based processes within a fully automated and closed manufacturing system for safe, standardized, and GMP compliant production of large-scale cartilage grafts.
除了部分或全部关节置换术,目前尚无手术方法可治疗与骨关节炎等进展性疾病相关的大而深的软骨缺损。在这项工作中,我们开发了一种灌注生物反应器系统,用于构建具有临床相关性的人软骨移植物,大小与单室膝关节表面置换(50 毫米直径×3 毫米厚)相关。开发了计算流体动力学模型,以在设计灌注室时优化流动剖面。使用开发的系统,可以在具有均匀分布的大 50 毫米直径支架中播种整个人体软骨细胞。经过两周的培养,在生物反应器中生长的组织具有活力且均匀的软骨样,生物力学性能接近天然软骨。相比之下,通过传统的手动生产工艺生成的组织高度不均匀,并且包含大的坏死区域。在这种大规模下对人体软骨组织进行前所未有的工程设计,为广泛的软骨缺损的临床治疗提供了功能生物替代物的实际前景,可能与手术或药物治疗相结合以支持植入物的耐用性。目前正在努力将基于放大的生物反应器的过程集成到全自动和封闭的制造系统中,以安全、标准化和符合 GMP 标准的方式生产大规模的软骨移植物。